Annie Mcguire Biography and Net Worth

SVP of Veracyte

Annie McGuire joined Veracyte in 2022 and serves as General Counsel and Chief People Officer. In this role, she oversees all aspects of the company’s legal functions and leads the company’s global Human Resources team. Ms. McGuire has more than 15 years of leadership experience in Fortune 100 and other healthcare companies. Prior to joining Veracyte, she served as General Counsel and Corporate Secretary at Rakuten Medical, Inc., a global biotechnology company. Prior to that, Ms. McGuire was Vice President, Legal, at MyoKardia, Inc., a biotechnology company focused on cardiovascular disease, where she helped lead the team through MyoKardia’s $13 billion acquisition by Bristol Myers Squibb. Before that, she spent 13 years at Amgen, Inc. where she held various legal and compliance leadership roles, including Senior Corporate Counsel for global commercial operations and employment and executive compensation. Ms. McGuire began her legal career at Proskauer Rose LLP in New York City. She holds a B.S. in Criminal Justice from Pace University, Summa Cum Laude, and a J.D. from New York Law School, Magna Cum Laude.

What is Annie Mcguire's net worth?: The estimated net worth of Annie Mcguire is at least $3.72 million as of December 4th, 2025. Mcguire owns 78,499 shares of Veracyte stock worth more than $3,721,638 as of December 4th. This net worth approximation does not reflect any other assets that Mcguire may own. Learn More about Annie Mcguire's net worth.
How do I contact Annie Mcguire?: The corporate mailing address for Mcguire and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Annie Mcguire's contact information.
Has Annie Mcguire been buying or selling shares of Veracyte?: In the last ninety days, Annie Mcguire has sold $325,900.60 in Veracyte stock. Most recently, Annie Mcguire sold 1,422 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $47.30, for a transaction totalling $67,260.60. Following the completion of the sale, the senior vice president now directly owns 78,499 shares of the company's stock, valued at $3,713,002.70. Learn More on Annie Mcguire's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Phillip Febbo (Insider), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Annie Mcguire (SVP), Marc Stapley (CEO), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 132,722 shares worth more than $5,646,695.43. The most recent insider tranaction occured on December, 4th when SVP Annie Mcguire sold 1,422 shares worth more than $67,260.60. Insiders at Veracyte own 1.4% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 12/4/2025.

Annie Mcguire Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2025	Sell	1,422	$47.30	$67,260.60	78,499
11/5/2025	Sell	6,466	$40.00	$258,640.00	82,973
9/19/2025	Sell	2,283	$33.69	$76,914.27	91,599

Annie Mcguire Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Today's Range

Now: $47.41

$46.02

$47.78

50 Day Range

MA: $39.11

$33.44

$49.38

2 Week Range

Now: $47.41

$22.61

$50.71

Volume

895,484 shs

Average Volume

974,443 shs

Market Capitalization

$3.75 billion

P/E Ratio

124.77

Dividend Yield

N/A

Beta

1.83